Comment On: "Targeting the PGD/CRTH/DP Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives"

Overview

Journal Drugs

Specialty Pharmacology

Date 2017 Oct 5

PMID 28975564

Authors

Insu Yilmaz

Murat Turk

Affiliations

Soon will be listed here.

References

Laidlaw T, Boyce J . Pathogenesis of aspirin-exacerbated respiratory disease and reactions. Immunol Allergy Clin North Am. 2013; 33(2):195-210. PMC: 3781366. DOI: 10.1016/j.iac.2012.11.006. View

Sladek K, Dworski R, Soja J, Sheller J, Nizankowska E, OATES J . Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med. 1994; 149(4 Pt 1):940-6. DOI: 10.1164/ajrccm.149.4.8143059. View

Pettipher R, Hunter M, Perkins C, Collins L, Lewis T, Baillet M . Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459. Allergy. 2014; 69(9):1223-32. DOI: 10.1111/all.12451. View

Lin D, Chandra R, Tan B, Zirkle W, Conley D, Grammer L . Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy. 2011; 25(4):205-8. PMC: 3390198. DOI: 10.2500/ajra.2011.25.3613. View

Laidlaw T, Boyce J . Aspirin-Exacerbated Respiratory Disease--New Prime Suspects. N Engl J Med. 2016; 374(5):484-8. DOI: 10.1056/NEJMcibr1514013. View

Bochenek G, Kuschill-Dziurda J, Szafraniec K, Plutecka H, Szczeklik A, Nizankowska-Mogilnicka E . Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis. J Allergy Clin Immunol. 2013; 133(1):98-103.e1-6. DOI: 10.1016/j.jaci.2013.07.004. View

Pierzchalska M, Szabo Z, Sanak M, Soja J, Szczeklik A . Deficient prostaglandin E2 production by bronchial fibroblasts of asthmatic patients, with special reference to aspirin-induced asthma. J Allergy Clin Immunol. 2003; 111(5):1041-8. DOI: 10.1067/mai.2003.1491. View

Rajan J, Wineinger N, Stevenson D, White A . Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature. J Allergy Clin Immunol. 2014; 135(3):676-81.e1. DOI: 10.1016/j.jaci.2014.08.020. View

Kupczyk M, Kuna P . Targeting the PGD/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives. Drugs. 2017; 77(12):1281-1294. PMC: 5529497. DOI: 10.1007/s40265-017-0777-2. View

10.

Cahill K, Bensko J, Boyce J, Laidlaw T . Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2014; 135(1):245-52. PMC: 4289104. DOI: 10.1016/j.jaci.2014.07.031. View

11.

Stevenson D, Sanchez-Borges M, Szczeklik A . Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol. 2001; 87(3):177-80. DOI: 10.1016/S1081-1206(10)62221-1. View

12.

Mita H, Endoh S, Kudoh M, Kawagishi Y, Kobayashi M, Taniguchi M . Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy. 2001; 56(11):1061-7. DOI: 10.1111/j.1398-9995.2001.00913.x. View

13.

Stevens W, Schleimer R . Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis. Immunol Allergy Clin North Am. 2016; 36(4):669-680. PMC: 5119761. DOI: 10.1016/j.iac.2016.06.004. View

14.

Bochenek G, Nagraba K, Nizankowska E, Szczeklik A . A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge. J Allergy Clin Immunol. 2003; 111(4):743-9. DOI: 10.1067/mai.2003.1387. View